ClinicalTrials.Veeva

Menu

Allo BMT in Advanced Leukemia or High Grade Lymphoma

Stanford University logo

Stanford University

Status

Completed

Conditions

Blood and Marrow Transplant (BMT)
Lymphomas: Non-Hodgkin
Leukemia
Lymphoma, Non-Hodgkin

Treatments

Procedure: ablative allogeneic hematopoietic cell transplantation

Study type

Interventional

Funder types

Other

Identifiers

NCT00186290
BMT34
74165
NCT00186290

Details and patient eligibility

About

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

Full description

To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

Enrollment

145 estimated patients

Sex

All

Ages

Under 50 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:HLA identical donor

  • adequate organ function
  • other life threatening disease

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems